Changes in mental health symptoms from pre-COVID-19 to COVID-19 among participants with systemic sclerosis from four countries: A Scleroderma Patient-centered Intervention Network (SPIN) Cohort study.
Adult
Aged
COVID-19
/ epidemiology
Canada
/ epidemiology
Cohort Studies
Female
France
/ epidemiology
Humans
Longitudinal Studies
Male
Mental Disorders
/ epidemiology
Mental Health
/ trends
Middle Aged
Patient-Centered Care
/ methods
Scleroderma, Systemic
/ epidemiology
United Kingdom
/ epidemiology
United States
/ epidemiology
Adult
Anxiety
COVID-19
Clinical epidemiology
Depressed mood
Depressive symptoms
Epidemiology
Pandemic
Scleroderma
Systemic sclerosis
Journal
Journal of psychosomatic research
ISSN: 1879-1360
Titre abrégé: J Psychosom Res
Pays: England
ID NLM: 0376333
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
05
07
2020
revised:
21
09
2020
accepted:
30
09
2020
pubmed:
19
10
2020
medline:
30
12
2020
entrez:
18
10
2020
Statut:
ppublish
Résumé
No studies have reported mental health symptom comparisons prior to and during COVID-19 in vulnerable medical populations. To compare anxiety and depression symptoms among people with a pre-existing medical condition and factors associated with changes. Pre-COVID-19 Scleroderma Patient-centered Intervention Network Cohort data were linked to COVID-19 data from April 2020. Multiple linear and logistic regression were used to assess factors associated with continuous change and ≥ 1 minimal clinically important difference (MCID) change for anxiety (PROMIS Anxiety 4a v1.0; MCID = 4.0) and depression (Patient Health Questionnaire-8; MCID = 3.0) symptoms, controlling for pre-COVID-19 levels. Mean anxiety symptoms increased 4.9 points (95% confidence interval [CI] 4.0 to 5.7). Depression symptom change was negligible (0.3 points; 95% CI -0.7 to 0.2). Compared to France (N = 159), adjusted anxiety symptom change scores were significantly higher in the United Kingdom (N = 50; 3.3 points, 95% CI 0.9 to 5.6), United States (N = 128; 2.5 points, 95% CI 0.7 to 4.2), and Canada (N = 98; 1.9 points, 95% CI 0.1 to 3.8). Odds of ≥1 MCID increase were 2.6 for the United Kingdom (95% CI 1.2 to 5.7) but not significant for the United States (1.6, 95% CI 0.9 to 2.9) or Canada (1.4, 95% CI 0.7 to 2.5). Older age and adequate financial resources were associated with less continuous anxiety increase. Employment and shorter time since diagnosis were associated with lower odds of a ≥ 1 MCID increase. Anxiety symptoms, but not depression symptoms, increased dramatically during COVID-19 among people with a pre-existing medical condition.
Identifiants
pubmed: 33070043
pii: S0022-3999(20)30824-2
doi: 10.1016/j.jpsychores.2020.110262
pmc: PMC7532799
pii:
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
110262Subventions
Organisme : NCATS NIH HHS
ID : KL2 TR003168
Pays : United States
Investigateurs
Catherine Fortuné
(C)
Amy Gietzen
(A)
Geneviève Guillot
(G)
Nancy Lewis
(N)
Michelle Richard
(M)
Maureen Sauvé
(M)
Joep Welling
(J)
Kim Fligelstone
(K)
Karen Gottesman
(K)
Catarina Leite
(C)
Elisabet Pérez
(E)
Murray Baron
(M)
Vanessa Malcarne
(V)
Maureen D Mayes
(MD)
Warren R Nielson
(WR)
Robert Riggs
(R)
Shervin Assassi
(S)
Carolyn Ells
(C)
Cornelia van den Ende
(C)
Tracy Frech
(T)
Daphna Harel
(D)
Monique Hinchcliff
(M)
Marie Hudson
(M)
Sindhu R Johnson
(SR)
Maggie Larche
(M)
Christelle Nguyen
(C)
Janet Pope
(J)
François Rannou
(F)
Tatiana Sofia Rodriguez Reyna
(TSR)
Anne A Schouffoer
(AA)
Maria E Suarez-Almazor
(ME)
Christian Agard
(C)
Alexandra Albert
(A)
Elana J Bernstein
(EJ)
Sabine Berthier
(S)
Lyne Bissonnette
(L)
Alessandra Bruns
(A)
Patricia Carreira
(P)
Benjamin Chaigne
(B)
Lorinda Chung
(L)
Chase Correia
(C)
Christopher Denton
(C)
Robyn Domsic
(R)
James V Dunne
(JV)
Bertrand Dunogue
(B)
Dominique Farge-Bancel
(D)
Paul R Fortin
(PR)
Jessica Gordon
(J)
Brigitte Granel-Rey
(B)
Pierre-Yves Hatron
(PY)
Ariane L Herrick
(AL)
Sabrina Hoa
(S)
Niall Jones
(N)
Artur Jose de B Fernandes
(AJB)
Suzanne Kafaja
(S)
Nader Khalidi
(N)
David Launay
(D)
Joanne Manning
(J)
Isabelle Marie
(I)
Maria Martin
(M)
Arsene Mekinian
(A)
Sheila Melchor
(S)
Mandana Nikpour
(M)
Louis Olagne
(L)
Susanna Proudman
(S)
Alexis Régent
(A)
Sébastien Rivière
(S)
David Robinson
(D)
Esther Rodriguez
(E)
Sophie Roux
(S)
Vincent Sobanski
(V)
Virginia Steen
(V)
Evelyn Sutton
(E)
Carter Thorne
(C)
Pearce Wilcox
(P)
Mara Cañedo Ayala
(MC)
Andrea Carboni-Jiménez
(A)
Maria Gagarine
(M)
Julia Nordlund
(J)
Nora Østbø
(N)
Danielle B Rice
(DB)
Kimberly A Turner
(KA)
Nicole Culos-Reed
(N)
Laura Dyas
(L)
Ghassan El-Baalbaki
(G)
Shannon Hebblethwaite
(S)
Laura Bustamante
(L)
Delaney Duchek
(D)
Kelsey Ellis
(K)
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Références
BMJ. 2019 Apr 9;365:l1476
pubmed: 30967483
Arthritis Care Res (Hoboken). 2011 Nov;63(11):1620-8
pubmed: 22034123
Psychosom Med. 2016 Jul-Aug;78(6):716-27
pubmed: 27187854
BMJ Open. 2013 Aug 07;3(8):
pubmed: 23929922
J Clin Epidemiol. 2020 Jun;122:115-128.e1
pubmed: 32105798
Lancet Psychiatry. 2020 Jun;7(6):547-560
pubmed: 32304649
J Psychosom Res. 2020 Jun;133:110113
pubmed: 32354463
J Clin Epidemiol. 2010 Nov;63(11):1179-94
pubmed: 20685078
Rheumatology (Oxford). 2018 Sep 1;57(9):1623-1631
pubmed: 29868924
J Affect Disord. 2009 Apr;114(1-3):163-73
pubmed: 18752852
Med Care. 2019 Nov;57(11):890-897
pubmed: 31415337
Nat Rev Dis Primers. 2015 Apr 23;1:15002
pubmed: 27189141
Lancet. 2020 Apr 4;395(10230):1100
pubmed: 32247383
Psychol Med. 2020 Jun;50(8):1368-1380
pubmed: 31298180
Arthritis Rheum. 2013 Nov;65(11):2737-47
pubmed: 24122180
Rheumatology (Oxford). 2010 Apr;49(4):789-96
pubmed: 20100794
Lancet. 2020 May 16;395(10236):1521
pubmed: 32416772
BMJ. 2020 Jan 28;368:m313
pubmed: 31992552
Rheumatology (Oxford). 2017 Aug 1;56(8):1302-1311
pubmed: 28431140
J Psychosom Res. 2020 Aug;135:110132
pubmed: 32521358
CMAJ. 2018 Jan 15;190(2):E44-E49
pubmed: 29335262